JP4582519B2 - ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用 - Google Patents

ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用 Download PDF

Info

Publication number
JP4582519B2
JP4582519B2 JP2004542927A JP2004542927A JP4582519B2 JP 4582519 B2 JP4582519 B2 JP 4582519B2 JP 2004542927 A JP2004542927 A JP 2004542927A JP 2004542927 A JP2004542927 A JP 2004542927A JP 4582519 B2 JP4582519 B2 JP 4582519B2
Authority
JP
Japan
Prior art keywords
amino
etoac
ethyl
nmr
oso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004542927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502214A5 (https=
JP2006502214A (ja
JP2006502214A6 (ja
Inventor
ウィリアム アレキサンダー デニー
グレアム ジェイ アトウェル
シャンジン ヤン
ウィリアム ロバート ウィルソン
アダム ヴォルン パターソン
Original Assignee
オークランド ユニサーヴィスィズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサーヴィスィズ リミテッド filed Critical オークランド ユニサーヴィスィズ リミテッド
Publication of JP2006502214A publication Critical patent/JP2006502214A/ja
Publication of JP2006502214A6 publication Critical patent/JP2006502214A6/ja
Publication of JP2006502214A5 publication Critical patent/JP2006502214A5/ja
Application granted granted Critical
Publication of JP4582519B2 publication Critical patent/JP4582519B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2004542927A 2002-10-08 2003-10-08 ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用 Expired - Fee Related JP4582519B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ521851A NZ521851A (en) 2002-10-08 2002-10-08 Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
NZ521851 2002-10-08
PCT/NZ2003/000225 WO2004033415A1 (en) 2002-10-08 2003-10-08 Nitroaniline-based alkylating agents and their use as prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010136139A Division JP2010265272A (ja) 2002-10-08 2010-06-15 ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用

Publications (4)

Publication Number Publication Date
JP2006502214A JP2006502214A (ja) 2006-01-19
JP2006502214A6 JP2006502214A6 (ja) 2006-04-06
JP2006502214A5 JP2006502214A5 (https=) 2006-11-16
JP4582519B2 true JP4582519B2 (ja) 2010-11-17

Family

ID=32089872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004542927A Expired - Fee Related JP4582519B2 (ja) 2002-10-08 2003-10-08 ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
JP2010136139A Withdrawn JP2010265272A (ja) 2002-10-08 2010-06-15 ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010136139A Withdrawn JP2010265272A (ja) 2002-10-08 2010-06-15 ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用

Country Status (8)

Country Link
US (1) US7776924B2 (https=)
EP (1) EP1558568A4 (https=)
JP (2) JP4582519B2 (https=)
CN (1) CN100546976C (https=)
AU (1) AU2003278628B2 (https=)
CA (1) CA2501388C (https=)
NZ (1) NZ521851A (https=)
WO (1) WO2004033415A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004285831B2 (en) * 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
JP4761899B2 (ja) * 2005-09-12 2011-08-31 Ｈｏｙａ株式会社 電子内視鏡システム
NZ549659A (en) * 2006-09-04 2008-12-24 Auckland Uniservices Ltd Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom
EP2350664B1 (en) 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
CN101723932B (zh) * 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
ES2877629T3 (es) 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
EP2888227B1 (en) * 2012-08-23 2020-07-29 Convert Pharmaceuticals SA Novel prodrugs and methods of use thereof
US10202408B2 (en) 2012-08-23 2019-02-12 Health Innovation Ventures B.V. Prodrugs and methods of use thereof
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP2016528217A (ja) 2013-07-26 2016-09-15 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
JP7327900B2 (ja) 2015-06-24 2023-08-16 スレッシュホールド ファーマシューティカルズ， インコーポレイテッド アジリジン含有ｄｎａアルキル化剤
CN106995815B (zh) * 2016-01-22 2020-09-01 南京农业大学 硝基还原酶基因pnr及其编码的蛋白和应用
CN106905184B (zh) * 2017-03-05 2019-03-29 北京化工大学 含有苯甲酰胺基团的氮芥类化合物及其制备方法和用途
EP3774743B1 (en) * 2018-03-29 2023-11-22 Achilles Medical Limited Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ240785A (en) * 1991-11-28 1995-08-28 Cancer Res Campaign Tech Substituted nitro aniline derivatives and medicaments

Also Published As

Publication number Publication date
CN1711236A (zh) 2005-12-21
WO2004033415A1 (en) 2004-04-22
NZ521851A (en) 2005-02-25
CA2501388C (en) 2011-01-04
US20050256191A1 (en) 2005-11-17
JP2010265272A (ja) 2010-11-25
AU2003278628A1 (en) 2004-05-04
EP1558568A1 (en) 2005-08-03
CN100546976C (zh) 2009-10-07
CA2501388A1 (en) 2004-04-22
JP2006502214A (ja) 2006-01-19
US7776924B2 (en) 2010-08-17
AU2003278628B2 (en) 2010-09-23
EP1558568A4 (en) 2006-10-18

Similar Documents

Publication Publication Date Title
JP2010265272A (ja) ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
US20250122194A1 (en) Novel small molecule inhibitors of tead transcription factors
JP2006502214A6 (ja) ニトロアニリン系のアルキル化剤およびそれらのプロドラッグとしての使用
CN110546151B (zh) 凋亡诱导剂
CN100335461C (zh) 芳基磺酰基苯胺脲
JP4760712B2 (ja) 新規ニトロフェニルマスタードおよびニトロフェニルアジリジンアルコールおよびそれらの対応するリン酸エステルおよびターゲットが決められた細胞毒性剤としてのそれらの使用
JP6200603B2 (ja) 化学療法剤としてのβ置換βアミノ酸および類似体
AP1308A (en) Diphenyl ether compounds useful in therapy.
TW200843728A (en) Antiparasitic agents
CN104718202A (zh) 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法
EP0124476B1 (de) Carboxamide, Verfahren zur Herstellung und pharmazeutische Präparate, die diese enthalten
SK2012003A3 (en) Phenoxybenzylamine derivatives as selective re-uptake inhibitors
US6448293B1 (en) Diphenyl ether compounds useful in therapy
CN108113989A (zh) 新型前体药物及其使用方法
JP2018016644A (ja) 化学療法剤としてのβ置換γアミノ酸および類似体
CN110724076A (zh) 对芳基二甲酰胺类化合物、包含其的药物组合物、其制备方法及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100223

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100727

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100823

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130910

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees